176 related articles for article (PubMed ID: 31587706)
1. Trends In Substance Use And Related Disorders: Analysis of the Epidemiological Survey of Substance Abuse 1995 to 2018.
Seitz NN; Lochbühler K; Atzendorf J; Rauschert C; Pfeiffer-Gerschel T; Kraus L
Dtsch Arztebl Int; 2019 Sep; 116(35-36):585-591. PubMed ID: 31587706
[TBL] [Abstract][Full Text] [Related]
2. The Use of Alcohol, Tobacco, Illegal Drugs and Medicines: An Estimate of Consumption and Substance-Related Disorders in Germany.
Atzendorf J; Rauschert C; Seitz NN; Lochbühler K; Kraus L
Dtsch Arztebl Int; 2019 Sep; 116(35-36):577-584. PubMed ID: 31587705
[TBL] [Abstract][Full Text] [Related]
3. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys.
McCabe SE; Cranford JA; West BT
Addict Behav; 2008 Oct; 33(10):1297-305. PubMed ID: 18632211
[TBL] [Abstract][Full Text] [Related]
4. [Epidemiology of substance use and substance use disorders in Germany].
Küfner H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Apr; 53(4):271-83. PubMed ID: 20232026
[TBL] [Abstract][Full Text] [Related]
5. The Use of Psychoactive Substances in Germany.
Rauschert C; Möckl J; Seitz NN; Wilms N; Olderbak S; Kraus L
Dtsch Arztebl Int; 2022 Aug; 119(31-32):527-534. PubMed ID: 35791270
[TBL] [Abstract][Full Text] [Related]
6. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
[TBL] [Abstract][Full Text] [Related]
7. [Cannabis and schizophrenia: demographic and clinical correlates].
Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
[TBL] [Abstract][Full Text] [Related]
8. Nosologic Comparisons of DSM-IV and DSM-5 Alcohol and Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.
Goldstein RB; Chou SP; Smith SM; Jung J; Zhang H; Saha TD; Pickering RP; Ruan WJ; Huang B; Grant BF
J Stud Alcohol Drugs; 2015 May; 76(3):378-88. PubMed ID: 25978823
[TBL] [Abstract][Full Text] [Related]
9. A descriptive epidemiology of substance use and substance use disorders in Nigeria during the early 21st century.
Gureje O; Degenhardt L; Olley B; Uwakwe R; Udofia O; Wakil A; Adeyemi O; Bohnert KM; Anthony JC
Drug Alcohol Depend; 2007 Nov; 91(1):1-9. PubMed ID: 17570618
[TBL] [Abstract][Full Text] [Related]
10. The impact of cohort substance use upon likelihood of transitioning through stages of alcohol and cannabis use and use disorder: Findings from the Australian National Survey on Mental Health and Wellbeing.
Degenhardt L; Glantz M; Bharat C; Peacock A; Lago L; Sampson N; Kessler RC
Drug Alcohol Rev; 2018 May; 37(4):546-556. PubMed ID: 29505682
[TBL] [Abstract][Full Text] [Related]
11. The prevalence and clinical course of sedative-hypnotic abuse and dependence in a large cohort.
Schuckit MA; Smith TL; Kramer J; Danko G; Volpe FR
Am J Drug Alcohol Abuse; 2002; 28(1):73-90. PubMed ID: 11853136
[TBL] [Abstract][Full Text] [Related]
12. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
Liraud F; Verdoux H
Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
[TBL] [Abstract][Full Text] [Related]
13. The use of psychoactive substances among adolescent students in an area in the south-west of China.
Liu Z; Zhou W; Lian Z; Mu Y; Cai Z; Cao J
Addiction; 2001 Feb; 96(2):247-50. PubMed ID: 11182869
[TBL] [Abstract][Full Text] [Related]
14. [Which psychiatric comorbidities in cannabis dependence during adolescence? Comparison of outpatients and controls].
Dorard G; Bungener C; Phan O; Edel Y; Corcos M; Berthoz S
Encephale; 2018 Feb; 44(1):2-8. PubMed ID: 27637871
[TBL] [Abstract][Full Text] [Related]
15. COgnitive enhancement and consumption of psychoactive Substances among Youth Students (COSYS): a cross-sectional study in France.
Batisse A; Leger S; Vicaut E; Gerbaud L; Djezzar S
Public Health; 2021 May; 194():75-78. PubMed ID: 33865150
[TBL] [Abstract][Full Text] [Related]
16. Substance use during the COVID-19 pandemic: What is really happening?
Mellos E; Paparrigopoulos T
Psychiatriki; 2022 Mar; 33(1):17-20. PubMed ID: 35255473
[TBL] [Abstract][Full Text] [Related]
17. Psychoactive substances consumption in French fishermen and merchant seamen.
Fort E; Massardier-Pilonchéry A; Bergeret A
Int Arch Occup Environ Health; 2010 Jun; 83(5):497-509. PubMed ID: 19885671
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence and risk factors for substance abuse and dependence among anaesthetists: a national survey].
Beaujouan L; Czernichow S; Pourriat JL; Bonnet F
Ann Fr Anesth Reanim; 2005 May; 24(5):471-9. PubMed ID: 15904727
[TBL] [Abstract][Full Text] [Related]
19. The relationship between tobacco use, substance-use disorders and mental health: results from the National Survey of Mental Health and Well-being.
Degenhardt L; Hall W
Nicotine Tob Res; 2001 Aug; 3(3):225-34. PubMed ID: 11506766
[TBL] [Abstract][Full Text] [Related]
20. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample.
Lev-Ran S; Le Strat Y; Imtiaz S; Rehm J; Le Foll B
Am J Addict; 2013 Jan; 22(1):7-13. PubMed ID: 23398220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
